


Application No.: 09/920,033

5. (Original) The compound of claim 2 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original) The compound of claim 2 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety
8. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (Twice Amended) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site within nucleotides 1-128 or nucleotides 149-14121 as set forth in SEQ ID NO: 3 [on a nucleic acid molecule encoding apolipoprotein B (SEQ ID NO: 3)].
12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.
14. (Original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.
- 15-19. (Withdrawn)
20. (Twice Amended) The compound of claim 1 targeted to a nucleic acid molecule

Application No.: 09/920,033

encoding apolipoprotein B [(SEQ ID NO: 3)], wherein said compound specifically hybridizes with nucleotides 1-128 or nucleotides 149-14121 as set forth in SEQ ID NO:3 and inhibits the expression of the long form of [a nucleic acid molecule encoding] apolipoprotein B, ApoB-100.

21. (New) The compound of claim 1, wherein said compound specifically hybridizes with nucleotides 1-114 or nucleotides 151-14121 as set forth in SEQ ID NO: 3.

 22. (New) The compound of claim 11, wherein said compound specifically hybridizes with at least an 8-nucleobase portion of an active site within nucleotides 1-114 or nucleotides 151-14121 as set forth in SEQ ID NO: 3.

23. (New) The compound of claim 20, wherein said compound specifically hybridizes with nucleotides 1-114 or nucleotides 151-14121 as set forth in SEQ ID NO: 3.

REMARKS

Claims 1, 11, and 20 are amended herein. The claims have been amended to specify with which nucleotides of the apolipoprotein B-encoding nucleic acid the compound hybridizes. Furthermore, claim 20 has been amended to clarify that it is the expression of the long form of the **protein** (ApoB-100) that is inhibited. Also, claims 21-23 are added. Support for the amendments to the claims and the new claims can be found throughout the specification, *e.g.*, at least at page 9, page 90, and page 91. The amendment includes no new matter.